Toxicity and antileishmanial activity of a new stable lipid suspension of amphotericin B.
about
Toxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B.Production and characterization of stable amphotericin-resistant amastigotes and promastigotes of Leishmania mexicana.Therapeutic and immunomodulatory activities of short-course treatment of murine visceral leishmaniasis with KALSOME™10, a new liposomal amphotericin B.Development of novel docetaxel phospholipid nanoparticles for intravenous administration: quality by design approachN-(2-hydroxypropyl)methacrylamide-amphotericin B (HPMA-AmB) copolymer conjugates as antileishmanial agents.Optimizing efficacy of Amphotericin B through nanomodification.Beyond oncology--application of HPMA copolymers in non-cancerous diseases.In vitro synergistic effect of amphotericin B and allicin on Leishmania donovani and L. infantum.Central nervous system toxicity associated with liposomal amphotericin B therapy for cutaneous leishmaniasis.Antileishmanial activity of nano-amphotericin B deoxycholate.Nanostructured delivery systems with improved leishmanicidal activity: a critical review.Activities of naphthylisoquinoline alkaloids and synthetic analogs against Leishmania major.Properties of An Oral Nanoformulation of A Molecularly Dispersed Amphotericin B Comprising A Composite Matrix of Theobroma Oil and Bee'S Wax.
P2860
Q33409652-B50A6C06-D263-45A7-8AFD-4B0D3CBCB37BQ33938137-6F0B207D-7F33-456F-8718-CFEF546FCD59Q35605511-DE8DEF78-A245-4ED8-A5E5-AED280A40221Q35868357-5A69E47D-A3B1-4DB9-8F74-412DC05BEF07Q37159459-DD49BCDF-2F9C-4924-98D2-9818A0C60B7CQ37178176-DF7A397A-3B3A-41C1-9FF5-54E0DFA6DDAFQ37631869-C61CDDF2-10B3-47EC-A177-B5DA2F334A80Q37643719-1E3A55F4-CCCB-4E3A-88EF-342A84BEABD7Q37860768-898BCC14-BA9A-4883-BED8-0AF17C0FFC5DQ39985840-E0269CD0-431A-48EF-9DBF-DBCADD973257Q40099567-2D22E781-A7CB-4532-972C-27A4F35C7D6CQ40211394-FAAFC407-7C7F-48B6-8C4E-5F6550FDC54CQ42321619-1C122735-223F-4703-B95E-049A96E51FF5
P2860
Toxicity and antileishmanial activity of a new stable lipid suspension of amphotericin B.
description
2003 nî lūn-bûn
@nan
2003 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Toxicity and antileishmanial activity of a new stable lipid suspension of amphotericin B.
@ast
Toxicity and antileishmanial activity of a new stable lipid suspension of amphotericin B.
@en
Toxicity and antileishmanial activity of a new stable lipid suspension of amphotericin B.
@nl
type
label
Toxicity and antileishmanial activity of a new stable lipid suspension of amphotericin B.
@ast
Toxicity and antileishmanial activity of a new stable lipid suspension of amphotericin B.
@en
Toxicity and antileishmanial activity of a new stable lipid suspension of amphotericin B.
@nl
prefLabel
Toxicity and antileishmanial activity of a new stable lipid suspension of amphotericin B.
@ast
Toxicity and antileishmanial activity of a new stable lipid suspension of amphotericin B.
@en
Toxicity and antileishmanial activity of a new stable lipid suspension of amphotericin B.
@nl
P2093
P2860
P1476
Toxicity and antileishmanial activity of a new stable lipid suspension of amphotericin B.
@en
P2093
Annette Gulik
Christian Bories
Gillian Barratt
Malika Larabi
Martine Appel
Philippe Legrand
Philippe M Loiseau
Simon L Croft
Vanessa Yardley
P2860
P304
P356
10.1128/AAC.47.12.3774-3779.2003
P407
P577
2003-12-01T00:00:00Z